Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF versus saline for gene expression in granulosa cells in poor ovarian response
IRCT20241218064088N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of filgrastim in poor ovarian response (POR) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: BMP15 gene expression, GDF9 gene expression and 5 more. Started Jan 2025; status: completed.
02
Drugs
filgrastim
03
Conditions
poor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20241218064088N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241218064088N1.